Last reviewed · How we verify

NCT03999528

14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis

Completed Last updated 9 June 2020
What this trial tests

trial testing 14-3-3η Protein assay in Rheumatoid Arthritis in 45 participants. Completed in 1 August 2019.

Timeline
1 May 2019
Primary endpoint
1 August 2019
1 August 2019

Quick facts

Lead sponsorAl-Azhar University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment45
Start date1 May 2019
Primary completion1 August 2019
Estimated completion1 August 2019
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

16 and older, female only, with Rheumatoid Arthritis or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Is to investigate the relation between 14-3-3η protein, disease activity, and bone mineral density in female patients with rheumatoid arthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03999528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing